Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study

BACKGROUND: Lorlatinib demonstrated efficacy (including intracranial activity) in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase I/II study (NCT01970865). BACKGROUND AND OBJECTIVE: This analysis describes the pharmacokinetics (PK) of lorlatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Joseph, O’Gorman, Melissa T., James, Lee P., Klamerus, Karen J., Mugundu, Ganesh, Pithavala, Yazdi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505377/
https://www.ncbi.nlm.nih.gov/pubmed/33937954
http://dx.doi.org/10.1007/s40262-021-01015-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505377/
https://www.ncbi.nlm.nih.gov/pubmed/33937954
http://dx.doi.org/10.1007/s40262-021-01015-z

Ejemplares similares